• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肝病中的血清补体

Serum complement in chronic liver disease.

作者信息

Potter B J, Trueman A M, Jones E A

出版信息

Gut. 1973 Jun;14(6):451-6. doi: 10.1136/gut.14.6.451.

DOI:10.1136/gut.14.6.451
PMID:4737028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1412744/
Abstract

Total serum haemolytic complement activity (CH(50)) and the serum concentrations of both the third and fourth components of the complement system (C3 and C4) have been measured in 29 control subjects, 92 patients with chronic hepatocellular disease, and eight patients with large duct biliary tract obstruction. The mean C4 concentration was reduced in all types of chronic liver disease studied. However, the mean CH(50) and C3 values were increased in compensated primary biliary cirrhosis, were relatively normal in non-cirrhotic chronic active hepatitis, and were decreased in cryptogenic cirrhosis, particularly when ascites was present. There was a significant correlation between CH(50) and C3 in patients with chronic liver disease but no correlation between CH(50) and C4 or between C3 and C4. Raised values for CH(50) and C3 in primary biliary cirrhosis may be due at least in part to concomitant cholestasis since these values tend to be raised in patients with large duct biliary tract obstruction. Although primary biliary cirrhosis, chronic active hepatitis, and cryptogenic cirrhosis are considered to be part of a spectrum of chronic liver disease associated with disturbed immunity, the results of this study emphasize that there are clearly definable differences between these diseases in terms of the pattern of changes in serum complement.

摘要

对29名对照者、92例慢性肝细胞疾病患者和8例大胆管胆道梗阻患者测定了血清总溶血补体活性(CH50)以及补体系统第三和第四成分(C3和C4)的血清浓度。在所研究的所有类型慢性肝病中,平均C4浓度均降低。然而,在代偿性原发性胆汁性肝硬化中,平均CH50和C3值升高;在非肝硬化性慢性活动性肝炎中相对正常;在隐源性肝硬化中降低,尤其是出现腹水时。慢性肝病患者中CH50与C3之间存在显著相关性,但CH50与C4之间以及C3与C4之间无相关性。原发性胆汁性肝硬化中CH50和C3值升高可能至少部分归因于合并胆汁淤积,因为在大胆管胆道梗阻患者中这些值往往升高。虽然原发性胆汁性肝硬化、慢性活动性肝炎和隐源性肝硬化被认为是与免疫紊乱相关的一系列慢性肝病的一部分,但本研究结果强调,这些疾病在血清补体变化模式方面存在明显可定义的差异。

相似文献

1
Serum complement in chronic liver disease.慢性肝病中的血清补体
Gut. 1973 Jun;14(6):451-6. doi: 10.1136/gut.14.6.451.
2
Profiles of serum complement in patients with hepatobiliary diseases.肝胆疾病患者的血清补体谱
Digestion. 1978;18(5-6):371-83. doi: 10.1159/000198223.
3
Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system.肝脏疾病中C3的循环转化产物。补体系统体内激活的证据。
Clin Exp Immunol. 1973 Aug;14(4):509-14.
4
Total haemolytic complement after liver transplantation and in liver disease.肝移植后及肝脏疾病中的总溶血补体
Transplantation. 1972 Jul;14(1):41-6. doi: 10.1097/00007890-197207000-00006.
5
Significance of serum complement levels in chronic liver disease.血清补体水平在慢性肝病中的意义。
Gastroenterology. 1972 Oct;63(4):653-9.
6
The serum concentration of the third component of complement beta-1C-beta-1A in liver disease.肝病中补体β-1C-β-1A第三成分的血清浓度。
Gut. 1971 Jul;12(7):574-8. doi: 10.1136/gut.12.7.574.
7
Differences between plasma and serum complement in patients with chronic liver disease.慢性肝病患者血浆和血清补体的差异
Clin Exp Immunol. 1976 Sep;25(3):403-9.
8
Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.原发性胆汁性肝硬化、活动性慢性(类狼疮样)肝炎、隐源性肝硬化及其他肝脏疾病中的组织抗体及其临床意义。
Clin Exp Immunol. 1966 Jul;1(3):237-62.
9
Complement activation in chronic liver disease.慢性肝病中的补体激活
Clin Exp Immunol. 1982 Mar;47(3):548-54.
10
[Behavior of complement activity in chronic liver disease].
Minerva Dietol Gastroenterol. 1977 Jul-Sep;23(3):137-44.

引用本文的文献

1
IgM Antibodies Targeting Malondialdehyde Promote Complement-Mediated Liver Injury in Alcohol-Related Liver Disease.靶向丙二醛的IgM抗体促进酒精性肝病中补体介导的肝损伤。
Liver Int. 2025 Oct;45(10):e70356. doi: 10.1111/liv.70356.
2
Complement C3 predicting acute-on-chronic liver failure in cirrhotic patients with bacterial infection within 90 days: a cohort study.补体C3预测肝硬化合并细菌感染患者90天内发生慢加急性肝衰竭:一项队列研究
Eur J Gastroenterol Hepatol. 2025 Jul 17;37(10):1147-54. doi: 10.1097/MEG.0000000000002991.
3
Chronic Liver Disease: A Mimic of Systemic Lupus Erythematosus.慢性肝病:系统性红斑狼疮的一种模仿疾病。
Cureus. 2021 Jul 30;13(7):e16765. doi: 10.7759/cureus.16765. eCollection 2021 Jul.
4
"Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.“赞美补体”:肝细胞癌治疗的机制见解与机遇
Front Oncol. 2021 Feb 24;10:627701. doi: 10.3389/fonc.2020.627701. eCollection 2020.
5
Roles of the complement system in alcohol-induced liver disease.补体系统在酒精性肝病中的作用。
Clin Mol Hepatol. 2020 Oct;26(4):677-685. doi: 10.3350/cmh.2020.0094. Epub 2020 Oct 1.
6
Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.使用新开发的基于核磁共振的检测方法对LP-Z脂蛋白颗粒进行表征及对肝病患者进行定量分析。
J Clin Med. 2020 Sep 10;9(9):2915. doi: 10.3390/jcm9092915.
7
Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection.慢性丙型肝炎病毒感染患者体内抗菌抗体功能的改变。
PLoS One. 2013 Jun 4;8(6):e64992. doi: 10.1371/journal.pone.0064992. Print 2013.
8
Serum markers may distinguish biliary atresia from other forms of neonatal cholestasis.血清标志物可区分胆汁淤积症与其他形式的新生儿胆汁淤积。
J Pediatr Gastroenterol Nutr. 2010 Apr;50(4):411-6. doi: 10.1097/MPG.0b013e3181cb42ee.
9
Role of Pneumolysin's complement-activating activity during pneumococcal bacteremia in cirrhotic rats.肺炎球菌溶血素的补体激活活性在肝硬化大鼠肺炎球菌血症中的作用。
Infect Immun. 1999 Jun;67(6):2862-6. doi: 10.1128/IAI.67.6.2862-2866.1999.
10
Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality.酒精性肝硬化患者获得性C3缺乏易导致感染并增加死亡率。
Gut. 1997 Apr;40(4):544-9. doi: 10.1136/gut.40.4.544.

本文引用的文献

1
Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure.肝硬化患者的血浆容量:其与门脉高压、腹水和肾衰竭的关系。
J Clin Invest. 1967 Aug;46(8):1297-308. doi: 10.1172/JCI105622.
2
The localization of in vivo bound complement in tissue section.体内结合补体在组织切片中的定位。
J Exp Med. 1962 Jan 1;115(1):63-82. doi: 10.1084/jem.115.1.63.
3
ESTIMATION OF THE SERUM BETA-1C GLOBULIN CONCENTRATION: ITS RELATION TO THE SERUM HEMOLYTIC COMPLEMENT TITER.血清β-1C球蛋白浓度的测定:其与血清溶血补体滴度的关系。
Pediatrics. 1965 May;35:765-9.
4
CHRONIC ACTIVE ("LUPOID") HEPATITIS; A CLINICAL, SEROLOGICAL, AND PATHOLOGICAL STUDY OF 20 PATIENTS.慢性活动性(“狼疮样”)肝炎;20例患者的临床、血清学及病理学研究
Ann Intern Med. 1965 Mar;62:425-62. doi: 10.7326/0003-4819-62-3-425.
5
SERUM LEVELS OF BETA-1C GLOBULIN, A COMPLEMENT COMPONENT, IN THE NEPHRITIDES, LIPOID NEPHROSIS, AND OTHER CONDITIONS.β1C球蛋白(一种补体成分)在肾炎、脂性肾病及其他病症中的血清水平
J Clin Invest. 1964 Aug;43(8):1507-17. doi: 10.1172/JCI105027.
6
Serum complement levels in systemic lupus erythematosus and other diseases.系统性红斑狼疮及其他疾病中的血清补体水平
Australas Ann Med. 1960 Feb;9:57-63. doi: 10.1111/imj.1960.9.1.57.
7
Serum complement in hepatobiliary diseases.肝胆疾病中的血清补体
Proc Soc Exp Biol Med. 1955 Dec;90(3):606-8. doi: 10.3181/00379727-90-22111.
8
The significance of the complement test in liver diseases with jaundice.补体试验在黄疸型肝病中的意义。
Acta Med Scand. 1953;144(4):268-74. doi: 10.1111/j.0954-6820.1953.tb15696.x.
9
Topics in clinical medicine. Complement levels in disease.临床医学专题。疾病中的补体水平。
Johns Hopkins Med J. 1967 May;120(5):337-43.
10
The reaction mechanism of human C5 in immune hemolysis.人补体C5在免疫溶血中的反应机制。
J Exp Med. 1970 Oct 1;132(4):775-93. doi: 10.1084/jem.132.4.775.